SCHEMBL394139

SCHEMBL394139

Cc1[nH]c(C=O)c(C)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
ALK Q9UM73 1/20 0.43
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 2/20 0.38
GAA P10253 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
NOTUM Q6P988 1/20 0.38
FLT4 P35916 4/20 0.37
KDR P35968 4/20 0.37
FLT3 P36888 4/20 0.37
KIT P10721 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19220179 0.83 ALDH1A1 (0.43) ALDH1A1ALKRAB9APOLBKMT2A
SCHEMBL11307800 0.83 CYP1A2 (0.57) ALDH1A1RAB9APOLBKMT2AMAPT
SCHEMBL7059773 0.82 RAB9A (0.42) ALDH1A1ALKRAB9AMAPTGAA
SCHEMBL1079494 0.82 ALDH1A1 (0.37) ALDH1A1ALKRAB9APOLBKMT2A
SCHEMBL27307246 0.82 GAA (0.44) ALDH1A1ALKRAB9AMAPTGAA
SCHEMBL7717391 0.81 ALDH1A1 (0.34) ALDH1A1ALKRAB9APOLBKMT2A
SCHEMBL18656646 0.81 ALDH1A1 (0.39) ALDH1A1RAB9APOLBKMT2AMAPT
SCHEMBL13303521 0.81 ALDH1A1 (0.39) ALDH1A1ALKRAB9APOLBKMT2A
SCHEMBL5403308 0.79 LMNA (0.45) ALDH1A1ALKRAB9APOLBKMT2A
SCHEMBL15331397 0.78 ALDH1A1 (0.58) ALDH1A1RAB9APOLBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121577791-A Gas chromatography detection method for residual quantity of 2-chloropyrrole in 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid serving as sunitinib intermediate 扬州市普林斯医药科技有限公司 2026-02-27 CN claimed
CN-117143083-A Synthesis method of VEGFR inhibitor Vorolianib 沈阳药科大学 2023-12-01 CN claimed
CN-112535660-B Three-level targeted pH sensitive type nano drug-loaded micelle and preparation method and application thereof 上海交通大学医学院附属第九人民医院 2022-10-25 CN claimed
CN-115124275-A Lithium silicate-based organic-inorganic composite concrete permeation protective agent 上海摩瑟尔科学技术有限公司 2022-09-30 CN claimed
CN-112535660-A Three-level targeted pH sensitive type nano drug-loaded micelle and preparation method and application thereof 上海交通大学医学院附属第九人民医院 2021-03-23 CN claimed
CN-111233841-A Sunitinib related substance and preparation method and application thereof 湖北扬信医药科技有限公司 2020-06-05 CN claimed
CN-105732583-B A kind of target compound for treating Gliblastoma 苏州麦迪耐斯医药科技有限公司 2018-05-04 CN claimed
CN-105732583-A Targeted compound for treating glioblastoma multiforme 苏州麦迪耐斯医药科技有限公司 2016-07-06 CN claimed
CN-105199715-A Fluorescence probe based on rhodamine B derivative as well as preparation method and application thereof UNIV HENAN POLYTECHNIC 2015-12-30 CN claimed
US-8466190-B2 Polymorphic forms of Sunitinib base NATCO PHARMA LIMITED (IN) 2013-06-18 US claimed
EP-2274303-B1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF TEVA PHARMA (IL) 2012-08-29 EP claimed
EP-2313371-B1 PROCESS FOR PREPARING A 3-PYRROLE SUBSTITUTED 2-INDOLINONE MALATE SALT MEDICHEM SA (ES) 2012-08-15 EP claimed
EP-2274303-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2011-01-19 EP claimed
US-20100160646-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-06-24 US claimed
WO-2009150523-A1 PROCESS FOR PREPARING A 3-PYRROLE SUBSTITUTED 2-INDOLINONE MALATE SALT MEDICHEM, S.A. (ES) 2009-12-17 WO claimed
WO-2009128083-A1 NOVEL POLYMORPHIC FORMS OF SUNITINIB BASE NATCO PHARMA LIMITED (IN) 2009-10-22 WO claimed
WO-2009124037-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-10-08 WO claimed
US-20090247767-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-10-01 US claimed
US-20260138994-A1 FLUORESCENT DYES CONTAINING FUSED TETRACYCLIC BIS-BORON HETEROCYCLE AND USES IN SEQUENCING ILLUMINA INC (US) 2026-05-21 US disclosed
WO-1999061422-A1 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 1999-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138994-A1 FLUORESCENT DYES CONTAINING FUSED TETRACYCLIC BIS-BORON HETEROCYCLE AND USES IN SEQUENCING POLL, POLM, NSUN2 ALDH1A1 2801/4885ALK 143/4885RAB9A 3286/4885
US-20100160646-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF KDR, ABL1, FLT4 ALDH1A1 1714/4885ALK 72/4885RAB9A 1117/4885
US-20090247767-A1 PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF KDR, ABL1, FLT4 ALDH1A1 1714/4885ALK 72/4885RAB9A 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.